Jaguar Health/$JAGX
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Jaguar Health
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Ticker
$JAGX
Sector
Primary listing
Employees
49
Headquarters
Website
Jaguar Health Metrics
BasicAdvanced
$5.5M
-
-$34.74
-0.13
-
Price and volume
Market cap
$5.5M
Beta
-0.13
52-week high
$15.48
52-week low
$1.10
Average daily volume
100K
Financial strength
Current ratio
0.814
Quick ratio
0.139
Long term debt to equity
196.513
Total debt to equity
731.819
Profitability
EBITDA (TTM)
-30.909
Gross margin (TTM)
81.92%
Net profit margin (TTM)
-341.90%
Operating margin (TTM)
-278.52%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-38.01%
Return on equity (TTM)
-411.57%
Valuation
Price to revenue (TTM)
0.133
Price to book
1.58
Price to tangible book (TTM)
-0.35
Price to free cash flow (TTM)
-0.06
Free cash flow yield (TTM)
-1,679.26%
Free cash flow per share (TTM)
-22.668
Growth
Revenue change (TTM)
12.45%
Earnings per share change (TTM)
-86.16%
3-year revenue growth (CAGR)
3.03%
Jaguar Health News
AllArticlesVideos
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Accesswire7 days ago
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Accesswire2 weeks ago
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Accesswire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jaguar Health stock?
Jaguar Health (JAGX) has a market cap of $5.5M as of December 01, 2025.
What is the P/E ratio for Jaguar Health stock?
The price to earnings (P/E) ratio for Jaguar Health (JAGX) stock is 0 as of December 01, 2025.
Does Jaguar Health stock pay dividends?
No, Jaguar Health (JAGX) stock does not pay dividends to its shareholders as of December 01, 2025.
When is the next Jaguar Health dividend payment date?
Jaguar Health (JAGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Jaguar Health?
Jaguar Health (JAGX) has a beta rating of -0.13. This means that it has an inverse relation to market volatility.